CL2022002423A1 - Métodos para tratar la enfermedad de fabry - Google Patents

Métodos para tratar la enfermedad de fabry

Info

Publication number
CL2022002423A1
CL2022002423A1 CL2022002423A CL2022002423A CL2022002423A1 CL 2022002423 A1 CL2022002423 A1 CL 2022002423A1 CL 2022002423 A CL2022002423 A CL 2022002423A CL 2022002423 A CL2022002423 A CL 2022002423A CL 2022002423 A1 CL2022002423 A1 CL 2022002423A1
Authority
CL
Chile
Prior art keywords
fabry disease
methods
galactosidase
patient
treatment
Prior art date
Application number
CL2022002423A
Other languages
English (en)
Spanish (es)
Inventor
Benjamin Elfrida
Wu Xiaoyang
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75267607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2022002423(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of CL2022002423A1 publication Critical patent/CL2022002423A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CL2022002423A 2020-03-06 2022-09-06 Métodos para tratar la enfermedad de fabry CL2022002423A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062986297P 2020-03-06 2020-03-06

Publications (1)

Publication Number Publication Date
CL2022002423A1 true CL2022002423A1 (es) 2023-05-05

Family

ID=75267607

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002423A CL2022002423A1 (es) 2020-03-06 2022-09-06 Métodos para tratar la enfermedad de fabry

Country Status (25)

Country Link
US (1) US20230136297A1 (cg-RX-API-DMAC7.html)
EP (2) EP4527454A3 (cg-RX-API-DMAC7.html)
JP (2) JP7749572B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220152547A (cg-RX-API-DMAC7.html)
CN (1) CN115427040A (cg-RX-API-DMAC7.html)
AR (1) AR122390A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021230371A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017881A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170718A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002423A1 (cg-RX-API-DMAC7.html)
DK (1) DK4114390T3 (cg-RX-API-DMAC7.html)
ES (1) ES3013813T3 (cg-RX-API-DMAC7.html)
FI (1) FI4114390T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250179T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070116T2 (cg-RX-API-DMAC7.html)
IL (1) IL296221A (cg-RX-API-DMAC7.html)
LT (1) LT4114390T (cg-RX-API-DMAC7.html)
MX (1) MX2022011030A (cg-RX-API-DMAC7.html)
PL (1) PL4114390T3 (cg-RX-API-DMAC7.html)
PT (1) PT4114390T (cg-RX-API-DMAC7.html)
RS (1) RS66530B1 (cg-RX-API-DMAC7.html)
SI (1) SI4114390T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500072T1 (cg-RX-API-DMAC7.html)
TW (1) TW202146020A (cg-RX-API-DMAC7.html)
WO (1) WO2021178737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3840753T (lt) * 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
WO2009102895A2 (en) * 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2012125402A2 (en) * 2011-03-11 2012-09-20 Amicus Therapeutics, Inc. Dosing regimens for the treatment of fabry disease
US11034946B2 (en) * 2017-10-05 2021-06-15 Research Foundation Of The City University Of New York Glycosylation independent proteins

Also Published As

Publication number Publication date
HUE070116T2 (hu) 2025-05-28
PL4114390T3 (pl) 2025-06-23
TW202146020A (zh) 2021-12-16
RS66530B1 (sr) 2025-03-31
ES3013813T3 (en) 2025-04-15
SI4114390T1 (sl) 2025-03-31
LT4114390T (lt) 2025-02-10
HRP20250179T1 (hr) 2025-04-11
EP4527454A2 (en) 2025-03-26
US20230136297A1 (en) 2023-05-04
AU2021230371A1 (en) 2022-09-29
JP2026016375A (ja) 2026-02-03
AR122390A1 (es) 2022-09-07
EP4114390B1 (en) 2024-12-04
SMT202500072T1 (it) 2025-03-12
EP4114390A1 (en) 2023-01-11
DK4114390T3 (da) 2025-02-24
CN115427040A (zh) 2022-12-02
JP7749572B2 (ja) 2025-10-06
KR20220152547A (ko) 2022-11-16
PT4114390T (pt) 2025-02-24
FI4114390T3 (fi) 2025-03-07
MX2022011030A (es) 2022-12-13
EP4527454A3 (en) 2025-09-24
WO2021178737A1 (en) 2021-09-10
BR112022017881A2 (pt) 2022-12-06
JP2023516753A (ja) 2023-04-20
IL296221A (en) 2022-11-01
CA3170718A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
MX2022001623A (es) Metodos para tratar la enfermedad de fabry en pacientes que tienen una mutacion en el gen gla.
CL2024000739A1 (es) Métodos para tratar fabry en pacientes con una mutación en el gen gla
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
CY1114815T1 (el) Χορηγηση θεραπευτικων χημικων ενωσεων στον εγκεφαλο και σε αλλους ιστους
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
ECSP045430A (es) Terapia de combinación para el tratamiento de cancer
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
AR119158A1 (es) Tratamientos de angioedema hereditario
ECSP22077573A (es) Método para el tratamiento de afecciones asociadas a covid-19
MX2024005237A (es) Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo.
BR112023002453A2 (pt) Composições de agente de via de estresse de replicação e métodos para tratar câncer
AR114392A1 (es) Tratamiento de pacientes con enfermedad de fabry clásica
CL2021003280A1 (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal
MX2025005378A (es) Metodos para el tratamiento de enfermedades cardiovasculares
AR122390A1 (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen una mutación en el gen gla
AR122298A1 (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen una mutación en el gen gla
CL2021001172A1 (es) Uso de tivozanib para tratar sujetos con cáncer refractario.
AR124892A1 (es) Métodos de tratamiento de insuficiencia cardíaca con vibegron
CL2025000332A1 (es) Tratamiento de la urticaria con inhibidores de jak.
AR124980A1 (es) Composiciones y métodos de tratamiento de la inflamación utilizando prevotella histicola
AR122819A1 (es) Métodos de administración segura de un oligonucleótido antisentido de irf5
BR112022006267A2 (pt) Método para tratar hiv com cabotegravir e rilpivirina
MX2016011002A (es) Tratamiento de angioedema hereditario con inhibidor c1.
AR122344A1 (es) Uso de reboxetina para tratar desórdenes del sistema nervioso
AR118933A1 (es) Dosificación del inhibidor de kras para el tratamiento de cánceres